Compare HWKN & ICUI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | HWKN | ICUI |
|---|---|---|
| Founded | 1938 | 1984 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Specialty Chemicals | Medical/Dental Instruments |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.3B | 3.6B |
| IPO Year | N/A | 1992 |
| Metric | HWKN | ICUI |
|---|---|---|
| Price | $143.17 | $155.31 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 2 | 5 |
| Target Price | ★ $200.00 | $179.50 |
| AVG Volume (30 Days) | 177.5K | ★ 248.9K |
| Earning Date | 01-28-2026 | 02-19-2026 |
| Dividend Yield | ★ 0.54% | N/A |
| EPS Growth | ★ 1.06 | N/A |
| EPS | ★ 3.95 | N/A |
| Revenue | $1,063,104,000.00 | ★ $2,320,363,000.00 |
| Revenue This Year | $12.68 | N/A |
| Revenue Next Year | $6.47 | N/A |
| P/E Ratio | $35.63 | ★ N/A |
| Revenue Growth | ★ 11.65 | N/A |
| 52 Week Low | $98.30 | $107.00 |
| 52 Week High | $186.15 | $165.17 |
| Indicator | HWKN | ICUI |
|---|---|---|
| Relative Strength Index (RSI) | 51.83 | 57.94 |
| Support Level | $125.15 | $148.71 |
| Resistance Level | $154.87 | $154.79 |
| Average True Range (ATR) | 6.23 | 4.63 |
| MACD | -0.66 | -0.08 |
| Stochastic Oscillator | 59.61 | 59.82 |
Hawkins Inc manufactures and sells a variety of chemicals and ingredients. The firm organizes itself into three segments based on the product type. The industrial segment, which generates the majority of revenue, sells private label bleach, caustic soda, sulfuric acid, hydrochloric acid, phosphoric acid, potassium hydroxide, and aqua ammonia. The water treatment segment sells chemicals and equipment used to treat potable water, municipal and industrial wastewater, industrial process water, and non-residential swimming pool water. The health and nutrition segment sells ingredients to food, beverage, personal care, and dietary supplement producers. The majority of revenue is gained from Water Treatment.
ICU Medical is a California-based pure-play infusion therapy company that provides consumables, systems, and services for virtually every component of the IV continuum of care. ICU has become one of the largest players in its industry following its acquisition of Hospira Infusion Systems from Pfizer in 2017 and Smiths Medical from Smiths Group in 2022. It holds top-tier positions across its three reporting segments: consumables (50% of consolidated revenue), infusion systems (30%), and vital care (20%). The combined entity remains primarily US-focused, generating over 60% of its sales domestically.